Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.73 USD
-0.01 (-0.36%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $2.66 -0.07 (-2.56%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Eledon Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 51 | 56 | 85 | 114 | 9 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 3 | 4 | 1 | 1 |
Total Current Assets | 56 | 60 | 88 | 116 | 10 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 49 | 49 | 0 |
Deposits & Other Assets | 33 | 33 | 33 | 33 | 1 |
Total Assets | 89 | 93 | 171 | 197 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 4 | 2 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 6 | 4 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 2 | 4 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 9 | 7 | 7 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 327 | 287 | 279 | 271 | 67 |
Retained Earnings | -243 | -203 | -115 | -80 | -58 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 83 | 84 | 164 | 191 | 9 |
Total Liabilities & Shareholder's Equity | 89 | 93 | 171 | 197 | 11 |
Total Common Equity | 83 | 84 | 164 | 191 | 9 |
Shares Outstanding | 24.20 | 13.70 | 14.30 | 15.10 | 0.70 |
Book Value Per Share | 3.45 | 6.14 | 11.47 | 12.62 | 13.53 |
Fiscal Year End for Eledon Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 43 | 51 | 60 | 71 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 5 | 3 | 2 |
Total Current Assets | NA | 48 | 56 | 63 | 74 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 33 | 33 | 33 | 33 |
Total Assets | NA | 81 | 89 | 96 | 107 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 0 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 3 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 4 | 3 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 2 | 2 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 6 | 5 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 328 | 327 | 325 | 323 |
Retained Earnings | NA | -253 | -243 | -234 | -223 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 75 | 83 | 91 | 100 |
Total Liabilities & Shareholder's Equity | NA | 81 | 89 | 96 | 107 |
Total Common Equity | 0 | 75 | 83 | 91 | 100 |
Shares Outstanding | 24.80 | 24.80 | 24.20 | 23.50 | 22.50 |
Book Value Per Share | 0.00 | 3.02 | 3.45 | 3.89 | 4.44 |